Iterative Health Secures $77M in Series C Funding to Accelerate Clinical Trial Infrastructure

Clinical trials don’t break loudly. They erode in silence. Timelines slip, enrollment stalls, and what should be a breakthrough drifts into backlog. The science holds up. The system doesn’t. That gap, the one nobody puts on a slide, is where the real cost lives.

Jonathan Ng built Iterative Health with a clear target in mind. Not the molecule, not the endpoint, but the machinery around it. Cambridge foundation, global footprint, and a bias toward fixing what actually slows medicine down. Now the response shows up in capital form. $77M in Series C financing, led by Intrepid Growth Partners and GV, with EDBI, Insight Partners, and Obvious Ventures backing the move. That’s not noise. That’s alignment.

Iterative Health operates where technology meets execution and neither gets to hide. AI-powered patient pre-screening that translates into actual enrollment, not just better dashboards. A clinical research network engineered to move faster, activate quicker, and deliver where most sites stall. Over 100 locations spanning North America, Europe, India, and Australia, all calibrated toward throughput. Less drag, more signal.

SKOUT carries its weight without theatrics. Real-time computer-aided detection during colonoscopy, picking up what the human eye can miss when fatigue or variability creeps in. A 27% increase in adenoma detection per procedure sharpens outcomes in a way that doesn’t need marketing spin. FDA cleared, commercially deployed, and quietly raising expectations across gastroenterology.

Performance is where the story tightens. 3x higher enrollment in IBD trials. 2+ patients randomized per business day. Activation timelines compressed to 74 days while much of the industry stretches past 120. With nearly 90% of U.S. trials missing enrollment targets, speed stops being a metric and starts becoming leverage.

Bill Kayser operating as President & CFO, Dana Feuchtbaum driving execution as COO, Nadege Gunn stepping in as Chief Medical Officer, Hepatology & Obesity, Laura Mantell building momentum as SVP, Partnerships, Daniel Wang steering the engine as SVP, Finance & Operations, and Julie Chang pushing the edge as VP, Growth. Structure matters when outcomes are the product.

The path here wasn’t scattered. Gastroenterology first, depth over breadth, credibility earned where results are measurable. Then expansion into hepatology, obesity, and now cardiology through partnerships like US Heart and Vascular. Focus compounds before scale ever does.

The clinical trial services market sits north of $66B and tracks toward $100B, but time is the asset that moves everything else. Iterative Health is compressing it, tightening cycles that used to drift, and turning operational drag into forward motion. $77M signals a shift toward platforms that don’t just analyze the problem but move it.